ADC Therapeutics ran higher with its exposure to antibody-drug conjugates (ADCs).
Even more exciting, industry leaders love ADC related stocks.
AbbVie recently said it would acquire Immunogen in a $10.1 billion deal. Merck even said it would acquire Daiichi to co-develop and commercialize ADCs, as well. Better, according to Pfizer’s CEO Albert Bourla, ADCs have become one of the hottest opportunities in oncology, which would explain why it recently acquired Seagen for $34 billion. Even better, Pfizer wants to acquire even more ADC companies.
All because ADCs can “deliver a cancer-killing therapy to specifically target and kill cancer cells and minimize damage to healthy ones. Meanwhile, standard chemotherapy is less selective – it can affect both cancer cells and healthy cells,” says CNBC.
With ADCT, the company announced the results of a very successful trial of a combination of ZYNLONTA and Rituximab — a monoclonal antibody medication used to treat certain autoimmune diseases and some cancers — to address relapsed follicular lymphoma (the second most common subtype of non-Hodgkin lymphoma).
“In this first-ever study evaluating the combination of ZYNLONTA and rituximab in patients with relapsed or refractory follicular lymphoma, the overall response rate was 96% and complete response rate was 85%, with a significant number of patients achieving an early response,” said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics.
While there’s potential for higher highs with ADCT and other ADC-related names, wait for the pullback to exhaust itself if you’re thinking of jumping in.
